Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Income from Continuing Operations: 2010-2025

Historic Income from Continuing Operations for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Sep 2025 value amounting to $40.1 million.

  • Ironwood Pharmaceuticals' Income from Continuing Operations rose 999.29% to $40.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $130.5 million, marking a year-over-year increase of 156.81%. This contributed to the annual value of $102.8 million for FY2024, which is 108.17% up from last year.
  • As of Q3 2025, Ironwood Pharmaceuticals' Income from Continuing Operations stood at $40.1 million, which was up 69.84% from $23.6 million recorded in Q2 2025.
  • Ironwood Pharmaceuticals' 5-year Income from Continuing Operations high stood at $391.3 million for Q2 2021, and its period low was -$1.1 billion during Q2 2023.
  • Its 3-year average for Income from Continuing Operations is -$102.6 million, with a median of $3.6 million in 2024.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first plummeted by 3,038.30% in 2023, then surged by 2,844.07% in 2025.
  • Quarterly analysis of 5 years shows Ironwood Pharmaceuticals' Income from Continuing Operations stood at $41.4 million in 2021, then grew by 18.16% to $48.9 million in 2022, then slumped by 567.15% to -$228.3 million in 2023, then skyrocketed by 145.63% to $104.2 million in 2024, then surged by 999.29% to $40.1 million in 2025.
  • Its Income from Continuing Operations was $40.1 million in Q3 2025, compared to $23.6 million in Q2 2025 and -$37.4 million in Q1 2025.